Home | Product Development | Corporate Information | Picture Gallery | Careers | Contact Us | Employee Login
 
 
 
  Our Products
  All Products
List of Generics
  Therapeutic Classes
 
CORE BRANDS
 
PRODUCT
Poze
 
Generic:
Pioglitazone HCl
 
Therapeutic Class:
Antidiabetic
 
Composition:
Poze tablet 15 mg
Each Poze tablet contains pioglitazone hydrochloride equivalent to pioglitazone ... 15 mg

Poze tablet 30 mg
Each Poze tablet contains pioglitazone hydrochloride equivalent to pioglitazone ... 30 mg

Poze tablet 45 mg
Each Poze tablet contains pioglitazone hydrochloride equivalent to pioglitazone ... 45 mg
 
Description:
Poze (pioglitazone hydrochloride) is an oral antidiabetic agent that is used in the management of type 2 diabetes. It acts primarily by decreasing insulin resistance. It improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. It reduces circulating insulin levels and improves glycemic control.
 
Indications:
Poze is indicated for type 2 diabetes mellitus (non-insulin dependant diabetes mellitus) as an adjunct to diet control and exercise.

Poze is recommended for monotherapy. It can also be used in combination with sulfonylureas, metformin or insulin when diet and exercise plus the single antidiabetic agent do not result in glycemic control.
 
Dosage:
Poze tablets can be taken once daily with or without meals. Skipping meals, while taking Poze is not advisable since this can lead to hypoglycemia.

Monotherapy
Poze monotherapy is initiated at 15 mg or 30 mg once daily for those patients whose diabetes is not controlled with diet and exercise.
Dose can be increased up to 45 mg once daily for those patients who do not adequately respond to initial dose of Poze.

Combination therapy
Combined therapy should be considered for those patients who do not adequately respond to monotherapy with Poze.

Sulfonylureas
Poze can be initiated with sulfonylureas at 15 mg to 30 mg once daily. If the patient experiences hypoglycemia, dose of sulfonylureas should be adjusted (decreased).

Metformin
Poze can be initiated with metformin at 15 mg to 30 mg once daily. The therapeutic effects of Poze are seen in combination with metformin in patients regardless of dose (low or high) of metformin which the patients are receiving.

Insulin
Poze can be initiated with insulin at 15 mg to 30 mg once daily. While giving Poze in combination with insulin, dose of insulin can be decreased by 10% to 25% if the patient is hypoglycemic or if plasma glucose concentrations decrease to less than 100 mg/dl. Further adjustments should be done based on glucose-lowering response. If there is a particular risk of hypoglycemia, patients on insulin should be given 15 mg of Poze once daily initially.

Maximum recommended dose
The maximum dose of Poze should not exceed 45 mg once daily.
 
Presentations:
Poze 15 mg is available in 14’s
Poze 30 mg is available in 14’s
Poze 45 mg is available in 14’s